Attitudes and Subjective Norms Regarding Medication for Opioid Use Disorder Among Individuals in Treatment for Opioid Use Disorder in the Greater St. Louis Area
Restricted accessResearch articleFirst published online July, 2025
Attitudes and Subjective Norms Regarding Medication for Opioid Use Disorder Among Individuals in Treatment for Opioid Use Disorder in the Greater St. Louis Area
Medication for opioid use disorder (MOUD) is safe and efficacious for treating opioid use disorder (OUD), yet there is limited understanding of how attitudes and subjective norms regarding MOUD among individuals with OUD may impede treatment uptake. Thus, the current study describes attitudes and subjective norms in a sample of individuals with OUD in the St. Louis area (N = 183) and compares outcomes among those who were and were not actively taking MOUD. Most endorsed positive views regarding pharmacologic treatment for OUD overall, but concerns about physical side effects, the daily nature of some MOUD options, and uncertainty about the relative risks and benefits of MOUD remained prevalent. Individuals reporting current MOUD use had more accepting attitudes and perceived subjective norms regarding MOUD compared to others, suggesting that interventions targeting improvements in the knowledge of, attitudes toward, and normalization of MOUD are needed to further improve uptake and retention in pharmacotherapy for OUD.
AbrahamA. J.KnudsenH. K.RieckmannT.RomanP. M. (2013). Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States. Journal of Studies on Alcohol and Drugs, 74(2), 258–265. https://doi.org/10.15288/jsad.2013.74.258
2.
AjaziE.DasguptaN.MarshallS. W.MonacoJ.HowardA. G.PreisserJ. S.SchwartzT. A. (2021). Revisiting the X BOT naltrexone clinical trial using a comprehensive survival analysis. Journal of Addiction Medicine, 16(4), 440–446. https://doi.org/10.1097/ADM.0000000000000931
AjzenI. (2005). Attitudes, personality and behaviour (p. 175). McGraw-Hill Education.
5.
Andraka-ChristouB.GabrielM.MadeiraJ.SilvermanR. D. (2019). Court personnel attitudes towards medication-assisted treatment: A state-wide survey. Journal of Substance Abuse Treatment, 104(2), 72–82. https://doi.org/10.1016/J.JSAT.2019.06.011
6.
AndrillaC. H. A.CoulthardC.PattersonD. G. (2018). Prescribing practices of rural physicians waivered to prescribe buprenorphine. American Journal of Preventive Medicine, 54(6), S208–S214. https://doi.org/10.1016/j.amepre.2018.02.006
7.
ArmitageC. J.ConnerM.LoachJ.WillettsD. (1999). Different perceptions of control: Applying an extended theory of planned behavior to legal and illegal drug use. Basic and Applied Social Psychology, 21(4), 301–316. https://doi.org/10.1207/S15324834BASP2104_4
8.
BarryC. L.McGintyE. E.PescosolidoB. A.GoldmanH. H. (2014). Stigma, discrimination, treatment effectiveness, and policy: Public views about drug addiction and mental illness. Psychiatric Services, 65(10), 1269–1272. https://doi.org/10.1176/appi.ps.201400140
9.
BergmanB. G.AshfordR. D.KellyJ. F. (2020). Attitudes toward opioid use disorder medications: Results from a U.S. National Study of individuals who resolved a substance use problem. Experimental and Clinical Psychopharmacology, 28(4), 449–461. https://doi.org/10.1037/pha0000325
10.
BosnjakM.AjzenI.SchmidtP. (2020). The theory of planned behavior: Selected recent advances and applications. Europe’s Journal of Psychology, 16(3), 1070–1071. https://doi.org/10.5964/ejop.v16i3.3107
11.
BrownB. S.BennG.JansenD. (1975a). Methadone maintenance: Some client opinions. American Journal of Psychiatry, 132(6), 623–626. https://doi.org/10.1176/AJP.132.6.623
ChouJ. L.PattonR.Cooper-SadloS.SwanC.BennettD. S.McDowellD.ZaarurA.SchindlerB. (2022). Stigma and medication for opioid use disorder (MOUD) among women. International Journal of Mental Health and Addiction, 20(11), 1–12. https://doi.org/10.1007/S11469-022-00768-3
15.
CioeK.BiondiB. E.EaslyR.SimardA.ZhengX.SpringerS. A. (2020). A systematic review of patients’ and providers’ perspectives of medications for treatment of opioid use disorder. Journal of Substance Abuse Treatment, 119(1), 108146. https://doi.org/10.1016/j.jsat.2020.108146
16.
DegenhardtL.LarneyS.KimberJ.GisevN.FarrellM.DobbinsT.WeatherburnD. J.GibsonA.MattickR.ButlerT.BurnsL. (2014). The impact of opioid substitution therapy on mortality post-release from prison: Retrospective data linkage study. Addiction, 109(8), 1306–1317. https://doi.org/10.1111/add.12536
17.
Dickson-GomezJ.SpectorA.WeeksM.GalletlyC.McDonaldM.MontaqueH. D. G. (2022). “You’re not supposed to be on it forever”: Medications to treat opioid use disorder (MOUD) related stigma among drug treatment providers and people who use opioids. Substance Abuse: Research and Treatment, 16, 1–10. https://doi.org/10.1177/11782218221103859
18.
Drug overdose dashboard- Fatal Overdoses. Missouri Department of Health & Senior Services. (2024). https://health.mo.gove/data/opioids/accessed: December 15, 2022.
19.
GreinerM. G.ShulmanM.ChooT. H.ScodesJ.PavlicovaM.CampbellA. N. C.NovoP.FishmanM.LeeJ. D.RotrosenJ.NunesE. V. (2021). Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse. Journal of Substance Abuse Treatment, 131(1), 108447. https://doi.org/10.1016/J.JSAT.2021.108447
20.
HallN. Y.LeL.MajmudarI.MihalopoulosC. (2021). Barriers to accessing opioid substitution treatment for opioid use disorder: A systematic review from the client perspective. Drug and Alcohol Dependence, 221(1), 108651. https://doi.org/10.1016/J.DRUGALCDEP.2021.108651
21.
Henry J., Kaiser Family Foundation. (2021). KFF - health policy analysis, polling, journalism and social impact media. KFF. https://www.kff.org/
22.
HoffmanL. A.VilsaintC. L.KellyJ. F. (2021). Attitudes toward opioid use disorder pharmacotherapy among recovery community center attendees. Journal of Substance Abuse Treatment, 131, 108464. https://doi.org/10.1016/J.JSAT.2021.108464
23.
HuhnA. S.HobelmannJ. G.StricklandJ. C.OylerG. A.BergeriaC. L.UmbrichtA.DunnK. E. (2020). Differences in availability and use of medications for opioid use disorder in residential treatment settings in the United States. JAMA Network Open, 3(2), Article e1920843. https://doi.org/10.1001/JAMANETWORKOPEN.2019.20843
24.
KellyS. M.BrownB. S.KatzE. C.O’GradyK. E.MitchellS. G.KingS.SchwartzR. P. (2012). A comparison of attitudes toward opioid agonist treatment among short-term buprenorphine patients. The American Journal of Drug and Alcohol Abuse, 38(3), 233–238. https://doi.org/10.3109/00952990.2011.643983
25.
Kennedy-HendricksA.BuschS. H.McGintyE. E.BachhuberM. A.NiederdeppeJ.GollustS. E.WebsterD. W.FiellinD. A.BarryC. L. (2016a). Primary care physicians’ perspectives on the prescription opioid epidemic. Drug and Alcohol Dependence, 165, 61–70. https://doi.org/10.1016/j.drugalcdep.2016.05.010
26.
Kennedy-HendricksA.McGintyE. E.BarryC. L. (2016b). Effects of competing narratives on public perceptions of opioid pain reliever addiction during pregnancy. Journal of Health Politics, Policy and Law, 41(5), 873–916. https://doi.org/10.1215/03616878-3632230
27.
KimmelS. D.WalleyA. Y.LiY.LinasB. P.LodiS.BernsonD.WeissR. D.SametJ. H.LarochelleM. R. (2020). Association of treatment with medications for opioid use disorder with mortality after hospitalization for injection drug use-associated infective endocarditis. JAMA Network Open, 3(10), Article e2016228. https://doi.org/10.1001/jamanetworkopen.2020.16228
28.
KnudsenH. K.RomanP. M.OserC. B. (2010). Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations. Journal of Addiction Medicine, 4(2), 99–107. https://doi.org/10.1097/ADM.0b013e3181b41a32
29.
LarochelleM. R.BernsonD.LandT.StopkaT. J.WangN.XuanZ.BagleyS. M.LiebschutzJ. M.WalleyA. Y. (2018). Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Annals of Internal Medicine, 169(3), 137–145. https://doi.org/10.7326/M17-3107
30.
LintzerisN.DunlopA. J.HaberP. S.LubmanD. I.GrahamR.HutchinsonS.ArunogiriS.HayesV.HjelmströmP.SvedbergA.PetersonS.TibergF. (2021). Patient-reported outcomes of treatment of opioid dependence with weekly and monthly subcutaneous depot vs daily sublingual buprenorphine: A randomized clinical trial. JAMA Network Open, 4(5), Article e219041. https://doi.org/10.1001/JAMANETWORKOPEN.2021.9041
31.
LouieD. L.AssefaM. T.McGovernM. P. (2019). Attitudes of primary care physicians toward prescribing buprenorphine: A narrative review. BMC Family Practice, 20(1), 1–8. https://doi.org/10.1186/S12875-019-1047-Z/PEER-REVIEW
32.
MaddenE. F. (2019). Intervention stigma: How medication-assisted treatment marginalizes patients and providers. Social Science & Medicine, 232(C), 324–331. https://doi.org/10.1016/J.SOCSCIMED.2019.05.027
33.
MaddenE. F.PrevedelS.LightT.SulzerS. H. (2021). Intervention stigma toward medications for opioid use disorder: A systematic review. Substance Use & Misuse, 56(14), 2181–2201. https://doi.org/10.1080/10826084.2021.1975749
34.
MarcusR.MakarenkoI.MazhnayaA.ZelenevA.PolonskyM.MaddenL.FilippovychS.DvoriakS.SpringerS. A.AlticeF. L. (2017). Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine. Drug and Alcohol Dependence, 179, 213–219. https://doi.org/10.1016/J.DRUGALCDEP.2017.07.010
35.
MattsonC. L.TanzL. J.QuinnK.KariisaM.PatelP.DavisN. L. (2021). Trends and geographic patterns in drug and synthetic opioid overdose deaths — United States, 2013–2019. MMWR. Morbidity and Mortality Weekly Report, 70(6), 202–207. https://doi.org/10.15585/mmwr.mm7006a4
Missour Overdose and Drug-involved mortality. University of Missouri St. Louis Addiction Science Team (2024) https://mimhaddisci.org/missourioverdose-data-2. Date accessed: November 12, 2022
38.
MoranG. E.SnyderC. M.NoftsingerR. F.NodaJ. K. (2017). Implementing medication-assisted treatment for opioid use disorder in rural primary Care: environmental scan volume 2 tools and resources (Vol. 2). AHRQ Publication No. 17.
39.
MorganJ. R.BarocasJ. A.MurphyS. M.EpsteinR. L.SteinM. D.SchackmanB. R.WalleyA. Y.LinasB. P. (2020). Comparison of rates of overdose and hospitalization after initiation of medication for opioid use disorder in the inpatient vs outpatient setting. JAMA Network Open, 3(12), Article e2029676. https://doi.org/10.1001/JAMANETWORKOPEN.2020.29676
40.
MorganJ. R.SchackmanB. R.WeinsteinZ. M.WalleyA. Y.LinasB. P. (2019). Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. Drug and Alcohol Dependence, 200, 34–39. https://doi.org/10.1016/J.DRUGALCDEP.2019.02.031
41.
National Academies of Sciences Engineering and Medicine. (2019). Medications for opioid use disorder save lives. National Academies Press. https://doi.org/10.17226/25310
42.
NayakS. M.HuhnA. S.BergeriaC. L.StrainE. C.DunnK. E. (2021). Familial perceptions of appropriate treatment types and goals for a family member who has opioid use disorder. Drug and Alcohol Dependence, 221(10), 108649. https://doi.org/10.1016/J.DRUGALCDEP.2021.108649
43.
NyashanuT.VisserM. (2022). Treatment barriers among young adults living with a substance use disorder in Tshwane, South Africa. Substance Abuse Treatment, Prevention, and Policy, 17(1), 1–11. https://doi.org/10.1186/S13011-022-00501-2/TABLES/2
44.
PaquetteC. E.SyvertsenJ. L.PolliniR. A. (2018). Stigma at every turn: Health services experiences among people who inject drugs. International Journal of Drug Policy, 57, 104. https://doi.org/10.1016/J.DRUGPO.2018.04.004
45.
PasmanE. (2021). Reducing stigma toward medication for opioid use disorder through social work education, research, and practice. Journal of Social Work Practice in the Addictions, 22(1), 1–7. https://doi.org/10.1080/1533256X.2021.1990643
46.
PasmanE.LeeG.KollinR.RodriguezB.AgiusE.MaddenE. F.ReskoS. M. (2022). Attitudes toward medication for opioid use disorder among substance use treatment providers. Substance Use & Misuse, 57(12), 1828–1836. https://doi.org/10.1080/10826084.2022.2115853
47.
PierceM.BirdS. M.HickmanM.MarsdenJ.DunnG.JonesA.MillarT. (2016). Impact of treatment for opioid dependence on fatal drug-related poisoning: A national cohort study in england. Addiction, 111(2), 298–308. https://doi.org/10.1111/add.13193
48.
SandersJ. J.RooseR. J.LubranoM. C.LucanS. C. (2013). Meaning and methadone: Patient perceptions of methadone dose and a model to promote adherence to maintenance treatment. Journal of Addiction Medicine, 7(5), 307–313. https://doi.org/10.1097/ADM.0B013E318297021E
49.
SchwartzR. P.KellyS. M.O’GradyK. E.MitchellS. G.PetersonJ. A.ReisingerH. S.AgarM. H.BrownB. S. (2008). Attitudes toward buprenorphine and methadone among opioid-dependent individuals. American Journal on Addictions, 17(5), 396–401. https://doi.org/10.1080/10550490802268835
50.
ShriveF. M.StuartH.QuanH.GhaliW. A. (2006). Dealing with missing data in a multi-question depression scale: A comparison of imputation methods. BMC Medical Research Methodology, 6(1), 57. https://doi.org/10.1186/1471-2288-6-57
51.
SteinM. D.KrauseC.RodgersE.SilwalA.HelmeD.SlaterM.BeardD.LewisN.LusterJ.StephensK.LefebvreC. (2023). Lessons learned from developing tailored community communication campaigns in the HEALing communities study. Journal of Health Communication, 28(10), 699–705. https://doi.org/10.1080/10810730.2023.2262948
52.
Substance Abuse and Mental Health Services Administration (SAMSHA). (2021). Treatment episode data set (TEDS): 2019. Admissions to and discharges from publicly funded substance use treatment. SAMSHA.
53.
SulzerS. H.PrevedelS.BarrettT.VossM. W.ManningC.MaddenE. F. (2021). Professional education to reduce provider stigma toward harm reduction and pharmacotherapy. Drugs: Education, Prevention and Policy, 29(5), 576–586. https://doi.org/10.1080/09687637.2021.1936457
54.
SzlykH. S.LiX.FiliatreauL. M.BierutL. J.BanksD.Cavazos-RehgP. (2023). Principal component regression analysis of familial psychiatric histories and suicide risk factors among adults with opioid use disorder. Journal of Psychiatric Research, 159(10), 6–13. https://doi.org/10.1016/J.JPSYCHIRES.2023.01.021
55.
UebelackerL. A.BaileyG.HermanD.AndersonB.SteinM. (2016). Patients’ beliefs about medications are associated with stated preference for methadone, buprenorphine, naltrexone, or no medication-assisted therapy following inpatient opioid detoxification. Journal of Substance Abuse Treatment, 66, 48–53. https://doi.org/10.1016/J.JSAT.2016.02.009
56.
VieraA.BrombergD. J.WhittakerS.RefslandB. M.StanojlovićM.NyhanK.AlticeF. L. (2020). Adherence to and retention in medications for opioid use disorder among adolescents and young adults. Epidemiologic Reviews, 42(1), 41. https://doi.org/10.1093/EPIREV/MXAA001
57.
WalleyA. Y.LodiS.LiY.BernsonD.Babakhanlou-ChaseH.LandT.LarochelleM. R. (2020). Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: A cohort analysis. Addiction, 115(8), 1496–1508. https://doi.org/10.1111/ADD.14964
58.
WinogradR.BudesaZ.BanksD.CarpenterR.WoodC.DuelloA.ThaterP.SmithC.TeamA. S. (2023). Outcomes of state targeted/opioid response grants and the medication first approach: Evidence of racial inequities in improved treatment access and retention. Substance Abuse, 44(3), 185–195. https://doi.org/10.31219/OSF.IO/SRXD3
59.
WinogradR. P.PresnallN.StringfellowE.WoodC.HornP.DuelloA.GreenL.RudderT. (2019). The case for a medication first approach to the treatment of opioid use disorder. The American Journal of Drug and Alcohol Abuse, 45(4), 333–340. https://doi.org/10.1080/00952990.2019.1605372
60.
WinogradR. P.WoodC. A.StringfellowE. J.PresnallN.DuelloA.HornP.RudderT. (2020). Implementation and evaluation of Missouri’s Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs. Journal of Substance Abuse Treatment, 108, 55–64. https://doi.org/10.1016/J.JSAT.2019.06.015
61.
WooJ.BhaleraoA.BaworM.BhattM.DennisB.MouravskaN.ZielinskiL.SamaanZ. (2017). “Don’t Judge a Book Its Cover”: a qualitative study of methadone patients’ experiences of stigma. Substance Abuse: Research and Treatment, 11, 1178221816685087. https://doi.org/10.1177/1178221816685087
62.
WoodsJ. S.JosephH. (2012). Reducing stigma through education to enhance medication-assisted recovery. Journal of Addictive Diseases, 31(3), 226–235. https://doi.org/10.1080/10550887.2012.694599
63.
WyseJ. J.GordonA. J.DobschaS. K.MorascoB. J.TiffanyE.DrexlerK.SandbrinkF.LovejoyT. I. (2018). Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: Historical perspective, lessons learned, and next steps. Substance Abuse, 39(2), 139–144. https://doi.org/10.1080/08897077.2018.1452327
64.
YenC. F.TsaiJ. J.WangP. W.YehY. C.LiuS. C.WangS. H.WangC. C. (2011). Unfavorable attitudes toward receiving methadone maintenance therapy and associated factors among the inmates using intravenous heroin. The Kaohsiung Journal of Medical Sciences, 27(1), 25–31. https://doi.org/10.1016/J.KJMS.2010.12.002
65.
ZallerN. D.BazaziA. R.VelazquezL.RichJ. D. (2009). Attitudes toward methadone among out-of-treatment minority injection drug users: Implications for health disparities. International Journal of Environmental Research and Public Health, 6(2), 787–797. https://doi.org/10.3390/ijerph6020787
66.
ZemoreS. E.AjzenI. (2014). Predicting substance abuse treatment completion using a new scale based on the theory of planned behavior. Journal of Substance Abuse Treatment, 46(2), 174–182. https://doi.org/10.1016/J.JSAT.2013.06.011
